Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1997 May;81(5):370–372. doi: 10.1136/bjo.81.5.370

Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension

C Linden 1, E Nuija 1, A Alm 1
PMCID: PMC1722192  PMID: 9227201

Abstract

AIMS—To evaluate whether long term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment.
METHODS—Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 µg/ml once daily for 6-12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser flare meter during 6-12 months' treatment in 16 patients.
RESULTS—On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3-8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2-2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study.
CONCLUSION—Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long term treatment.



Full Text

The Full Text of this article is available as a PDF (108.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Mean difference (pretreatment IOP − IOP during follow up) versus time after cessation of latanoprost treatment. Error bars denote 95% confidence interval. (n = 26.)

Figure 2  .

Figure 2  

Open in a new tab

Mean flare intensity versus time. Filled circles represent treated eyes, open circles untreated eyes. Error bars denote half the 95% confidence interval. (n =10-16.)

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743–1752. doi: 10.1016/s0161-6420(95)30798-1. [DOI] [PubMed] [Google Scholar]
  2. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991 Nov;109(11):1564–1568. doi: 10.1001/archopht.1991.01080110100045. [DOI] [PubMed] [Google Scholar]
  3. Alm A., Villumsen J., Törnquist P., Mandahl A., Airaksinen J., Tuulonen A., Marsk A., Resul B., Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 1993 Sep;100(9):1312–1317. doi: 10.1016/s0161-6420(93)31482-x. [DOI] [PubMed] [Google Scholar]
  4. Camras C. B., Bhuyan K. C., Podos S. M., Bhuyan D. K., Master R. W. Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci. 1987 Jun;28(6):921–926. [PubMed] [Google Scholar]
  5. Camras C. B., Bito L. Z., Eakins K. E. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977 Dec;16(12):1125–1134. [PubMed] [Google Scholar]
  6. Camras C. B., Schumer R. A., Marsk A., Lustgarten J. S., Serle J. B., Stjernschantz J., Bito L. Z., Podos S. M. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992 Dec;110(12):1733–1738. doi: 10.1001/archopht.1992.01080240073034. [DOI] [PubMed] [Google Scholar]
  7. Crawford K., Kaufman P. L., Gabelt B. T. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987 Aug;6(8):1035–1044. doi: 10.3109/02713688709034874. [DOI] [PubMed] [Google Scholar]
  8. Crawford K., Kaufman P. L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987 Aug;105(8):1112–1116. doi: 10.1001/archopht.1987.01060080114039. [DOI] [PubMed] [Google Scholar]
  9. Giuffrè G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222(3):139–141. doi: 10.1007/BF02173538. [DOI] [PubMed] [Google Scholar]
  10. Hotehama Y., Mishima H. K. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol. 1993;37(3):259–269. [PubMed] [Google Scholar]
  11. Lee P. Y., Podos S. M., Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984 Sep;25(9):1087–1093. [PubMed] [Google Scholar]
  12. Lütjen-Drecoll E., Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988 Nov;47(5):761–769. doi: 10.1016/0014-4835(88)90043-7. [DOI] [PubMed] [Google Scholar]
  13. Menon I. A., Trope G. E., Basu P. K., Wakeham D. C., Persad S. D. Binding of timolol to iris-ciliary body and melanin: an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs. J Ocul Pharmacol. 1989 Winter;5(4):313–324. doi: 10.1089/jop.1989.5.313. [DOI] [PubMed] [Google Scholar]
  14. Nilsson S. F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989 May;48(5):707–716. doi: 10.1016/0014-4835(89)90011-0. [DOI] [PubMed] [Google Scholar]
  15. Schlecht L. P., Brubaker R. F. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology. 1988 Sep;95(9):1212–1216. doi: 10.1016/s0161-6420(88)33026-5. [DOI] [PubMed] [Google Scholar]
  16. Stjernschantz J., Selén G., Sjöquist B., Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513–518. [PubMed] [Google Scholar]
  17. Tamm E., Rittig M., Lütjen-Drecoll E. Elektronenmikroskopische und immunhistochemische Untersuchungen zur augendrucksenkenden Wirkung von Prostaglandin F2 alpha. Fortschr Ophthalmol. 1990;87(6):623–629. [PubMed] [Google Scholar]
  18. Toris C. B., Camras C. B., Yablonski M. E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993 Sep;100(9):1297–1304. doi: 10.1016/s0161-6420(93)31484-3. [DOI] [PubMed] [Google Scholar]
  19. Villumsen J., Alm A. Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol. 1989 Jun;73(6):419–426. doi: 10.1136/bjo.73.6.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ziai N., Dolan J. W., Kacere R. D., Brubaker R. F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993 Oct;111(10):1351–1358. doi: 10.1001/archopht.1993.01090100059027. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES